Alpha Tau Medical (DRTS)

Executive Summary

Alpha Tau Medical is an Israeli clinical-stage biotechnology company pioneering Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), a novel intratumoral radiotherapy platform that uses Radium-224 to deliver potent, localized alpha radiation to solid tumors while sparing healthy tissue. This approach offers a significant advancement over conventional external beam radiotherapy and beta-emitting brachytherapy, with potential applications across multiple solid tumor types. The company is publicly traded (NASDAQ: DRTS) with a market capitalization of approximately $681 million, reflecting early-stage investor enthusiasm for its differentiated technology platform and broad potential in oncology.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 interim data from Alpha DaRT combination with pembrolizumab in head and neck cancer (NCT05047094)55% success
• Q2 2027FDA regulatory update for Alpha DaRT in recurrent glioblastoma (potential Breakthrough Device designation or IDE approval)60% success
• Q1 2027New strategic partnership or licensing deal for select territories or indications40% success